Biotie Therapies - Decisions of general meeting

Resolutions of The Annual General Meeting of Biotie Therapies Corp.

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 29 MAY 2009 at 12:15

RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.

The Annual General Meeting of Biotie Therapies Corp. was held on 29
May 2009.

Adoption of financial statements for the financial year 1 January -
31 December 2008 and booking of the loss of the financial year

The Annual General Meeting of Shareholders adopted the financial
statements for the financial year 1 January - 31 December 2008. The
Annual General Meeting resolved in accordance with the proposal of
the Board of Directors that the loss of the financial year shall be
transferred to the unrestricted equity and no dividend shall be paid.

The Annual General Meeting discharged the members of the Board of
Directors and the President and CEO from liability concerning the
financial year from 1 January - 31 December 2008.

The Board of Directors and auditors

The number of the members of the Board of Directors was resolved to
be seven. Juha Jouhki, Ann Hanham, Bernd Kastler, Pauli Marttila,
Riku Rautsola, Christoph Schröder and Pierre Serrure were re-elected
as the members of the Board of Directors.

The Annual General Meeting resolved that the remuneration payable to
the members of the Board of Directors be EUR 3,000 per month for the
Chairman and each member residing abroad and EUR 1,500 per month for
each member residing in Finland. In addition, reasonable travelling
expenses for the meetings shall be compensated.

PricewaterhouseCoopers Oy, a firm of auditors approved by the Central
Chamber of Commerce, and Janne Rajalahti, Authorized Public
Accountant, were re-elected as auditors of the company.

At the organization meeting of the new Board of Directors, which
convened immediately after the Annual General Meeting, Juha Jouhki
was elected as the Chairman of the Board of Directors and Pauli
Marttila as the deputy chairman.

Authorisation of the Board of Directors to decide on an issuance of
shares as well as the issuance options and other special rights
entitling to shares

The Annual General Meeting authorised the Board of Directors to
resolve on one issues which contains the right to issue new shares or
dispose of the shares in the possession of the company and to issue
options or other specific rights to the shares pursuant to chapter 10
of the Finnish Companies Act. The authorisation consists of up to
25,000,000 shares in the aggregate. A maximum of 819,000 own shares
in the possession of the company may be conveyed.

The authorisation does not exclude the Board of Directors' right to
decide on a directed share issue. The authorisation may be used for
material arrangements from the company's point of view, such as
financing or implementing business arrangements or investments or for
other such purposes determined by the Board in which case a weighty
financial reason for issuing shares, options or other specific rights
and possibly directing a share issue exists. Further, the
authorisation may be used to create new share-based incentive
schemes.

The Board of Directors was authorised to decide on all other terms
and conditions of a share issue, options and other specific share
entitlements as referred to in chapter 10 of the Finnish Companies
Act, including the payment period, determination grounds for the
subscription price and subscription price or allocation of shares,
option rights or specific rights free of charge or that the
subscription price may be paid besides in cash also by other assets
either partially or entirely.

The authorisation is effective until 30 June 2010 and it does not
supersede earlier authorisations.

President and CEO's review

Timo Veromaa, President and CEO, discussed the company's operations,
results and future in his review. The presentation is available on
the Company's website at www.biotie.com.

The minutes of the meeting will be available on the Company's website
as from 12 June 2009.

Turku, 29 May 2009

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media